Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.

Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average

Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75% over this period, while the latter has dropped 32%.

2 Beaten-Down Stocks to Buy and Hold for a Decade

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

3 Of My Favorite Biotech Stocks Under $10

Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice President of Research Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAMBRIDGE, MA / ACCESS Newswire / September 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened. The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health Service (NHS) seasonal vaccination programs.

Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK

Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. MRNY, the YieldMax MRNA Option Income Strategy ETF, fails to deliver significant drawdown protection or outperformance in flat or correcting markets. MRNY's high headline yield is misleading, as structural NAV erosion and high expenses erode real returns, making it unattractive compared to holding MRNA directly.

Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying risk condition.

Moderna says updated next-generation COVID shot shows strong immune response in patients

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains CAMBRIDGE, MA / ACCESS Newswire / September 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA),which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids

Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.

Mizuho's Jared Holz: There's not much value left in vaccine stocks

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.

The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula of Spikevax CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability and immunogenicity of the 2025-2026 formula of Spikevax showed, on average, greater than an 8-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

Moderna (MRNA) reached $23.51 at the closing of the latest trading day, reflecting a -7.4% change compared to its last close.

Moderna (MRNA) Declines More Than Market: Some Information for Investors

Shares of two entertainment giants pushed higher for a second straight day as investors weighed the possibility of a takeover bid, while vaccine makers came under pressure following a report that health officials from the Trump administration seek to link COVID-19 vaccines with child deaths.

S&P 500 Gains and Losses Today: Warner Bros. and Paramount Extend Gains; Moderna Plunges

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.

Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children.  The report comes as Health and Human Services Secretary Robert F.

Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots

CNBC's Angelica Peebles joins 'Money Movers' to discuss Trump officials reported plan to link child deaths to covid shots.

Trump officials to link child deaths to covid shots, according to reports

Real-time stock quote and overview for MRNA